Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Non-Current Assets: 2022-2024

Historic Non-Current Assets for Stoke Therapeutics (STOK) over the last 3 years, with Dec 2024 value amounting to $38.8 million.

  • Stoke Therapeutics' Non-Current Assets rose 121.19% to $87.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.8 million, marking a year-over-year increase of 121.19%. This contributed to the annual value of $38.8 million for FY2024, which is 198.38% up from last year.
  • Latest data reveals that Stoke Therapeutics reported Non-Current Assets of $38.8 million as of FY2024, which was up 198.38% from $13.0 million recorded in FY2023.
  • In the past 5 years, Stoke Therapeutics' Non-Current Assets ranged from a high of $38.8 million in FY2024 and a low of $12.0 million during FY2022.
  • Over the past 3 years, Stoke Therapeutics' median Non-Current Assets value was $13.0 million (recorded in 2023), while the average stood at $21.3 million.
  • Data for Stoke Therapeutics' Non-Current Assets shows a peak YoY skyrocketed of 198.38% (in 2024) over the last 5 years.
  • Yearly analysis of 3 years shows Stoke Therapeutics' Non-Current Assets stood at $12.0 million in 2022, then increased by 8.39% to $13.0 million in 2023, then surged by 198.38% to $38.8 million in 2024.